Literature DB >> 11104579

Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.

J A Bristol1, C Orsini, P Lindinger, J Thalhamer, S I Abrams.   

Abstract

Mutations in ras proto-oncogenes are commonly found in a diversity of malignancies and may encode unique, non-self epitopes for T cell-mediated antitumor activity. In a BALB/c (H-2(d)) murine model, we have identified a single peptide sequence derived from the ras oncogenes that contained both CD8(+) and CD4(+) T cell epitopes in a nested configuration. This peptide reflected ras sequence 4-16, and contained the substitution of Gly to Val at position 12 ¿i.e., 4-16(Val12)¿. Mice immunized with this 13-mer peptide induced a strong antigen (Ag)-specific CD4(+) proliferative response in vitro. In contrast, mice inoculated with the wild-type ras sequence failed to generate a peptide-specific T cell response. Additionally, mice immunized with the ras 4-16(Val12) peptide concomitantly displayed an Ag-specific CD8(+) cytotoxic T lymphocyte (CTL) response, as determined by lysis of syngeneic tumor target cells incubated with the nominal 9-mer nested epitope peptide ¿i.e., 4-12(Val12)¿, as well as lysis of tumor target cells expressing the corresponding ras codon 12 mutation. Analysis of the Valpha- and Vbeta-chains of the T cell receptor (TCR) expressed by these CTL revealed usage of the Valpha1 and Vbeta9 subunits, consistent with the TCR phenotype of anti-ras Val12 CTL lines produced by in vivo immunization with the nominal peptide epitope alone. Moreover, immunization with the nested epitope peptide, as compared to immunization with either the 9-mer CTL peptide alone or an admixture of the 9-mer CTL peptide with an overlapping 13-mer CD4(+) T cell helper peptide ¿i.e., 5-17(Val12)¿ lacking the class I N-terminus anchor site, enhanced the production of the CD8(+) T cell response. Finally, immunization with plasmid DNA encoding the ras 4-16(Val12) sequence led to the induction of both Ag-specific proliferative and cytotoxic responses. Overall, these results suggested that a single peptide immunogen containing nested mutant ras-specific CD4(+) and CD8(+) T cell epitopes: (1) can be processed in vivo to induce both subset-specific T lymphocyte responses; and (2) leads to the generation of a quantitatively enhanced CD8(+) CTL response, likely due to the intimate coexistence of CD4(+) help, which may have implications in peptide- or DNA-based immunotherapies. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11104579     DOI: 10.1006/cimm.2000.1712

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  4 in total

1.  K-ras mutation targeted to gastric tissue progenitor cells results in chronic inflammation, an altered microenvironment, and progression to intraepithelial neoplasia.

Authors:  Tomoyuki Okumura; Russell E Ericksen; Shigeo Takaishi; Sophie S W Wang; Zinaida Dubeykovskiy; Wataru Shibata; Kelly S Betz; Sureshkuma Muthupalani; Arlin B Rogers; James G Fox; Anil K Rustgi; Timothy C Wang
Journal:  Cancer Res       Date:  2010-10-19       Impact factor: 12.701

2.  Designing of CD8+ and CD8+-overlapped CD4+ epitope vaccine by targeting late and early proteins of human papillomavirus.

Authors:  Satyavani Kaliamurthi; Gurudeeban Selvaraj; Aman Chandra Kaushik; Ke-Ren Gu; Dong-Qing Wei
Journal:  Biologics       Date:  2018-10-02

3.  Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity.

Authors:  Nadia Mensali; Amalie Grenov; Niladri Bhusan Pati; Pierre Dillard; Marit Renée Myhre; Gustav Gaudernack; Gunnar Kvalheim; Else Marit Inderberg; Oddmund Bakke; Sébastien Wälchli
Journal:  Oncoimmunology       Date:  2019-01-11       Impact factor: 8.110

4.  In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine.

Authors:  Ali Namvar; Azam Bolhassani; Gholamreza Javadi; Zahra Noormohammadi
Journal:  Sci Rep       Date:  2019-10-23       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.